{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T03:45:43Z","timestamp":1790999143752,"version":"4.1.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1007\/s00702-022-02471-y","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T10:14:57Z","timestamp":1645092897000},"page":"239-259","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Tau proteins in blood as biomarkers of Alzheimer\u2019s disease and other proteinopathies"],"prefix":"10.1007","volume":"129","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3977-6995","authenticated-orcid":false,"given":"Federico","family":"Verde","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"issue":"5","key":"2471_CR1","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK et al (2021) Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol 141(5):709\u2013724. https:\/\/doi.org\/10.1007\/s00401-021-02275-6","journal-title":"Acta Neuropathol"},{"key":"2471_CR2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200861","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy NR, Horie K, Sato C, Bateman RJ (2020) Blood plasma phosphorylated-tau isoforms track CNS change in Alzheimer\u2019s disease. J Exp Med. https:\/\/doi.org\/10.1084\/jem.20200861","journal-title":"J Exp Med"},{"issue":"9","key":"2471_CR3","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/jnnp-2020-323487","volume":"91","author":"A Benussi","year":"2020","unstructured":"Benussi A, Karikari TK, Ashton N et al (2020) Diagnostic and prognostic value of serum NfL and p-Tau181 in frontotemporal lobar degeneration. J Neurol Neurosurg Psychiatry 91(9):960\u2013967. https:\/\/doi.org\/10.1136\/jnnp-2020-323487","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"2471_CR4","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82(4):239\u2013259. https:\/\/doi.org\/10.1007\/BF00308809","journal-title":"Acta Neuropathol"},{"issue":"8","key":"2471_CR5","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/alz.12301","volume":"17","author":"AM Brickman","year":"2021","unstructured":"Brickman AM, Manly JJ, Honig LS et al (2021) Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. Alzheimers Dement 17(8):1353\u20131364. https:\/\/doi.org\/10.1002\/alz.12301","journal-title":"Alzheimers Dement"},{"issue":"1","key":"2471_CR6","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1212\/WNL.0000000000008696","volume":"94","author":"E Cavedo","year":"2020","unstructured":"Cavedo E, Lista S, Houot M et al (2020) Plasma tau correlates with basal forebrain atrophy rates in people at risk for Alzheimer disease. Neurology 94(1):e30\u2013e41. https:\/\/doi.org\/10.1212\/WNL.0000000000008696","journal-title":"Neurology"},{"key":"2471_CR7","doi-asserted-by":"publisher","first-page":"112","DOI":"10.3389\/fnagi.2020.00112","volume":"12","author":"NC Chen","year":"2020","unstructured":"Chen NC, Chen HL, Li SH et al (2020) Plasma levels of alpha-synuclein, abeta-40 and T-tau as biomarkers to predict cognitive impairment in Parkinson\u2019s disease. Front Aging Neurosci 12:112. https:\/\/doi.org\/10.3389\/fnagi.2020.00112","journal-title":"Front Aging Neurosci"},{"issue":"1","key":"2471_CR8","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41398-021-01476-7","volume":"11","author":"SD Chen","year":"2021","unstructured":"Chen SD, Huang YY, Shen XN et al (2021) Longitudinal plasma phosphorylated tau 181 tracks disease progression in Alzheimer\u2019s disease. Transl Psychiatry 11(1):356. https:\/\/doi.org\/10.1038\/s41398-021-01476-7","journal-title":"Transl Psychiatry"},{"issue":"8","key":"2471_CR9","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1021\/acschemneuro.1c00010","volume":"12","author":"MJ Chiu","year":"2021","unstructured":"Chiu MJ, Yang SY, Chen TF et al (2021) Synergistic association between plasma Abeta1-42 and p-tau in Alzheimer\u2019s disease but not in Parkinson\u2019s disease or frontotemporal dementia. ACS Chem Neurosci 12(8):1376\u20131383. https:\/\/doi.org\/10.1021\/acschemneuro.1c00010","journal-title":"ACS Chem Neurosci"},{"issue":"11","key":"2471_CR10","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1136\/jnnp-2021-327370","volume":"92","author":"JR Chong","year":"2021","unstructured":"Chong JR, Ashton NJ, Karikari TK et al (2021) Blood-based high sensitivity measurements of beta-amyloid and phosphorylated tau as biomarkers of Alzheimer\u2019s disease: a focused review on recent advances. J Neurol Neurosurg Psychiatry 92(11):1231\u20131241. https:\/\/doi.org\/10.1136\/jnnp-2021-327370","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"2471_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13024-021-00476-x","volume":"16","author":"DC Chung","year":"2021","unstructured":"Chung DC, Roemer S, Petrucelli L, Dickson DW (2021) Cellular and pathological heterogeneity of primary tauopathies. Mol Neurodegen 16(1):57. https:\/\/doi.org\/10.1186\/s13024-021-00476-x","journal-title":"Mol Neurodegen"},{"issue":"1","key":"2471_CR12","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13195-021-00805-8","volume":"13","author":"C Clark","year":"2021","unstructured":"Clark C, Lewczuk P, Kornhuber J et al (2021) Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer\u2019s disease pathology and clinical disease progression. Alzheimers Res Ther 13(1):65. https:\/\/doi.org\/10.1186\/s13195-021-00805-8","journal-title":"Alzheimers Res Ther"},{"issue":"12","key":"2471_CR13","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1016\/j.jalz.2016.06.001","volume":"12","author":"JL Dage","year":"2016","unstructured":"Dage JL, Wennberg AMV, Airey DC et al (2016) Levels of tau protein in plasma are associated with neurodegeneration and cognitive function in a population-based elderly cohort. Alzheimers Dement 12(12):1226\u20131234. https:\/\/doi.org\/10.1016\/j.jalz.2016.06.001","journal-title":"Alzheimers Dement"},{"issue":"4","key":"2471_CR14","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/brain\/awaa054","volume":"143","author":"F de Wolf","year":"2020","unstructured":"de Wolf F, Ghanbari M, Licher S et al (2020) Plasma tau, neurofilament light chain and amyloid-beta levels and risk of dementia; a population-based cohort study. Brain 143(4):1220\u20131232. https:\/\/doi.org\/10.1093\/brain\/awaa054","journal-title":"Brain"},{"issue":"8","key":"2471_CR15","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1136\/jnnp-2017-317260","volume":"89","author":"MS Foiani","year":"2018","unstructured":"Foiani MS, Woollacott IO, Heller C et al (2018) Plasma tau is increased in frontotemporal dementia. J Neurol Neurosurg Psychiatry 89(8):804\u2013807. https:\/\/doi.org\/10.1136\/jnnp-2017-317260","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"2471_CR16","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/S1474-4422(18)30285-0","volume":"17","author":"J Fortea","year":"2018","unstructured":"Fortea J, Carmona-Iragui M, Benejam B et al (2018) Plasma and CSF biomarkers for the diagnosis of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study. Lancet Neurol 17(10):860\u2013869. https:\/\/doi.org\/10.1016\/S1474-4422(18)30285-0","journal-title":"Lancet Neurol"},{"issue":"10242","key":"2471_CR17","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1016\/S0140-6736(20)30689-9","volume":"395","author":"J Fortea","year":"2020","unstructured":"Fortea J, Vilaplana E, Carmona-Iragui M et al (2020) Clinical and biomarker changes of Alzheimer\u2019s disease in adults with Down syndrome: a cross-sectional study. Lancet 395(10242):1988\u20131997. https:\/\/doi.org\/10.1016\/S0140-6736(20)30689-9","journal-title":"Lancet"},{"issue":"8","key":"2471_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S1474-4422(17)30159-X","volume":"16","author":"GB Frisoni","year":"2017","unstructured":"Frisoni GB, Boccardi M, Barkhof F et al (2017) Strategic roadmap for an early diagnosis of Alzheimer\u2019s disease based on biomarkers. Lancet Neurol 16(8):661\u2013676. https:\/\/doi.org\/10.1016\/S1474-4422(17)30159-X","journal-title":"Lancet Neurol"},{"key":"2471_CR19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2021.4222","author":"MC Gonzalez","year":"2021","unstructured":"Gonzalez MC, Ashton NJ, Gomes BF et al (2021) Association of plasma p-tau181 and p-tau231 concentrations with cognitive decline in patients with probable dementia with Lewy bodies. JAMA Neurol. https:\/\/doi.org\/10.1001\/jamaneurol.2021.4222","journal-title":"JAMA Neurol"},{"key":"2471_CR20","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000012513","author":"MJ Grothe","year":"2021","unstructured":"Grothe MJ, Moscoso A, Ashton NJ et al (2021) Associations of fully automated CSF and novel plasma biomarkers with Alzheimer disease neuropathology at autopsy. Neurology. https:\/\/doi.org\/10.1212\/WNL.0000000000012513","journal-title":"Neurology"},{"issue":"3","key":"2471_CR21","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1002\/mds.28370","volume":"36","author":"S Hall","year":"2021","unstructured":"Hall S, Janelidze S, Londos E et al (2021) Plasma phospho-tau identifies Alzheimer\u2019s co-pathology in patients with lewy body disease. Mov Disord 36(3):767\u2013771. https:\/\/doi.org\/10.1002\/mds.28370","journal-title":"Mov Disord"},{"issue":"1","key":"2471_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1001\/archpsyc.61.1.95","volume":"61","author":"H Hampel","year":"2004","unstructured":"Hampel H, Buerger K, Zinkowski R et al (2004) Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch Gen Psychiatry 61(1):95\u2013102. https:\/\/doi.org\/10.1001\/archpsyc.61.1.95","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"2471_CR23","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/S1474-4422(06)70355-6","volume":"5","author":"O Hansson","year":"2006","unstructured":"Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer\u2019s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5(3):228\u2013234. https:\/\/doi.org\/10.1016\/S1474-4422(06)70355-6","journal-title":"Lancet Neurol"},{"issue":"3","key":"2471_CR24","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/s0304-3940(00)01697-9","volume":"297","author":"C Hesse","year":"2001","unstructured":"Hesse C, Rosengren L, Andreasen N et al (2001) Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297(3):187\u2013190. https:\/\/doi.org\/10.1016\/s0304-3940(00)01697-9","journal-title":"Neurosci Lett"},{"issue":"5","key":"2471_CR25","doi-asserted-by":"publisher","first-page":"e671","DOI":"10.1212\/WNL.0000000000011226","volume":"96","author":"I Ill\u00e1n-Gala","year":"2021","unstructured":"Ill\u00e1n-Gala I, Lle\u00f3 A, Karydas A et al (2021) Plasma tau and neurofilament light in frontotemporal lobar degeneration and Alzheimer disease. Neurology 96(5):e671\u2013e683. https:\/\/doi.org\/10.1212\/WNL.0000000000011226","journal-title":"Neurology"},{"issue":"4","key":"2471_CR26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","volume":"14","author":"CR Jack Jr","year":"2018","unstructured":"Jack CR Jr, Bennett DA, Blennow K et al (2018) NIA-AA Research Framework: toward a biological definition of Alzheimer\u2019s disease. Alzheimers Dement 14(4):535\u2013562. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.018","journal-title":"Alzheimers Dement"},{"issue":"3","key":"2471_CR27","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S et al (2020a) Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 26(3):379\u2013386. https:\/\/doi.org\/10.1038\/s41591-020-0755-1","journal-title":"Nat Med"},{"issue":"1","key":"2471_CR28","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1038\/s41467-020-15436-0","volume":"11","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Stomrud E, Smith R et al (2020b) Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer\u2019s disease. Nat Commun 11(1):1683. https:\/\/doi.org\/10.1038\/s41467-020-15436-0","journal-title":"Nat Commun"},{"key":"2471_CR29","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12395","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Palmqvist S, Leuzy A et al (2021a) Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma Abeta42\/Abeta40 and p-tau. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12395","journal-title":"Alzheimers Dement"},{"issue":"2","key":"2471_CR30","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1001\/jamaneurol.2020.4201","volume":"78","author":"S Janelidze","year":"2021","unstructured":"Janelidze S, Berron D, Smith R et al (2021b) Associations of plasma phospho-Tau217 levels with tau positron emission tomography in early Alzheimer disease. JAMA Neurol 78(2):149\u2013156. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4201","journal-title":"JAMA Neurol"},{"issue":"5","key":"2471_CR31","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/S1474-4422(20)30071-5","volume":"19","author":"TK Karikari","year":"2020","unstructured":"Karikari TK, Pascoal TA, Ashton NJ et al (2020) Blood phosphorylated tau 181 as a biomarker for Alzheimer\u2019s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. Lancet Neurol 19(5):422\u2013433. https:\/\/doi.org\/10.1016\/S1474-4422(20)30071-5","journal-title":"Lancet Neurol"},{"issue":"2","key":"2471_CR32","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1038\/s41380-020-00923-z","volume":"26","author":"TK Karikari","year":"2021","unstructured":"Karikari TK, Benedet AL, Ashton NJ et al (2021) Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative. Mol Psychiatry 26(2):429\u2013442. https:\/\/doi.org\/10.1038\/s41380-020-00923-z","journal-title":"Mol Psychiatry"},{"issue":"4","key":"2471_CR33","doi-asserted-by":"publisher","first-page":"e282","DOI":"10.1212\/WNL.0000000000004860","volume":"90","author":"R La Joie","year":"2018","unstructured":"La Joie R, Bejanin A, Fagan AM et al (2018) Associations between [(18)F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. Neurology 90(4):e282\u2013e290. https:\/\/doi.org\/10.1212\/WNL.0000000000004860","journal-title":"Neurology"},{"issue":"3","key":"2471_CR34","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s00401-020-02195-x","volume":"140","author":"J Lantero Rodriguez","year":"2020","unstructured":"Lantero Rodriguez J, Karikari TK, Suarez-Calvet M et al (2020) Plasma p-tau181 accurately predicts Alzheimer\u2019s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. Acta Neuropathol 140(3):267\u2013278. https:\/\/doi.org\/10.1007\/s00401-020-02195-x","journal-title":"Acta Neuropathol"},{"key":"2471_CR35","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.202114408","author":"A Leuzy","year":"2021","unstructured":"Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O (2021) Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Mol Med. https:\/\/doi.org\/10.15252\/emmm.202114408","journal-title":"EMBO Mol Med"},{"issue":"1","key":"2471_CR36","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/ane.13517","volume":"145","author":"WT Lin","year":"2022","unstructured":"Lin WT, Shaw JS, Cheng FY, Chen PH (2022) Plasma total tau predicts executive dysfunction in Parkinson\u2019s disease. Acta Neurol Scand 145(1):30\u201337. https:\/\/doi.org\/10.1111\/ane.13517","journal-title":"Acta Neurol Scand"},{"issue":"1","key":"2471_CR37","doi-asserted-by":"publisher","first-page":"4304","DOI":"10.1038\/s41467-021-24319-x","volume":"12","author":"A Lle\u00f3","year":"2021","unstructured":"Lle\u00f3 A, Zetterberg H, Pegueroles J et al (2021) Phosphorylated tau181 in plasma as a potential biomarker for Alzheimer\u2019s disease in adults with Down syndrome. Nat Commun 12(1):4304. https:\/\/doi.org\/10.1038\/s41467-021-24319-x","journal-title":"Nat Commun"},{"issue":"2","key":"2471_CR38","doi-asserted-by":"publisher","first-page":"fcab073","DOI":"10.1093\/braincomms\/fcab073","volume":"3","author":"FZ Lussier","year":"2021","unstructured":"Lussier FZ, Benedet AL, Therriault J et al (2021) Plasma levels of phosphorylated tau 181 are associated with cerebral metabolic dysfunction in cognitively impaired and amyloid-positive individuals. Brain Commun 3(2):fcab073. https:\/\/doi.org\/10.1093\/braincomms\/fcab073","journal-title":"Brain Commun"},{"issue":"194","key":"2471_CR39","doi-asserted-by":"publisher","first-page":"194re2","DOI":"10.1126\/scitranslmed.3006446","volume":"5","author":"LF Maia","year":"2013","unstructured":"Maia LF, Kaeser SA, Reichwald J et al (2013) Changes in amyloid-beta and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci Transl Med 5(194):194re2. https:\/\/doi.org\/10.1126\/scitranslmed.3006446","journal-title":"Sci Transl Med"},{"issue":"1","key":"2471_CR40","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s13195-021-00944-y","volume":"13","author":"JD Marks","year":"2021","unstructured":"Marks JD, Syrjanen JA, Graff-Radford J et al (2021) Comparison of plasma neurofilament light and total tau as neurodegeneration markers: associations with cognitive and neuroimaging outcomes. Alzheimers Res Ther 13(1):199. https:\/\/doi.org\/10.1186\/s13195-021-00944-y","journal-title":"Alzheimers Res Ther"},{"issue":"17","key":"2471_CR41","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1212\/WNL.0000000000003246","volume":"87","author":"N Mattsson","year":"2016","unstructured":"Mattsson N, Zetterberg H, Janelidze S et al (2016) Plasma tau in Alzheimer disease. Neurology 87(17):1827\u20131835. https:\/\/doi.org\/10.1212\/WNL.0000000000003246","journal-title":"Neurology"},{"issue":"11","key":"2471_CR42","doi-asserted-by":"publisher","first-page":"3234","DOI":"10.1093\/brain\/awaa286","volume":"143","author":"N Mattsson-Carlgren","year":"2020","unstructured":"Mattsson-Carlgren N, Janelidze S, Palmqvist S et al (2020) Longitudinal plasma p-tau217 is increased in early stages of Alzheimer\u2019s disease. Brain 143(11):3234\u20133241. https:\/\/doi.org\/10.1093\/brain\/awaa286","journal-title":"Brain"},{"issue":"6","key":"2471_CR43","doi-asserted-by":"publisher","first-page":"e14022","DOI":"10.15252\/emmm.202114022","volume":"13","author":"N Mattsson-Carlgren","year":"2021","unstructured":"Mattsson-Carlgren N, Janelidze S, Bateman RJ et al (2021) Soluble P-tau217 reflects amyloid and tau pathology and mediates the association of amyloid with tau. EMBO Mol Med 13(6):e14022. https:\/\/doi.org\/10.15252\/emmm.202114022","journal-title":"EMBO Mol Med"},{"issue":"5","key":"2471_CR44","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/ana.25885","volume":"88","author":"D Mengel","year":"2020","unstructured":"Mengel D, Janelidze S, Glynn RJ, Liu W, Hansson O, Walsh DM (2020) Plasma NT1 tau is a specific and early marker of Alzheimer\u2019s disease. Ann Neurol 88(5):878\u2013892. https:\/\/doi.org\/10.1002\/ana.25885","journal-title":"Ann Neurol"},{"issue":"9","key":"2471_CR45","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1001\/jamaneurol.2017.1359","volume":"74","author":"MM Mielke","year":"2017","unstructured":"Mielke MM, Hagen CE, Wennberg AMV et al (2017) Association of plasma total tau level with cognitive decline and risk of mild cognitive impairment or dementia in the Mayo Clinic Study on aging. JAMA Neurol 74(9):1073\u20131080. https:\/\/doi.org\/10.1001\/jamaneurol.2017.1359","journal-title":"JAMA Neurol"},{"issue":"8","key":"2471_CR46","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1016\/j.jalz.2018.02.013","volume":"14","author":"MM Mielke","year":"2018","unstructured":"Mielke MM, Hagen CE, Xu J et al (2018) Plasma phospho-tau181 increases with Alzheimer\u2019s disease clinical severity and is associated with tau- and amyloid-positron emission tomography. Alzheimers Dement 14(8):989\u2013997. https:\/\/doi.org\/10.1016\/j.jalz.2018.02.013","journal-title":"Alzheimers Dement"},{"issue":"9","key":"2471_CR47","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaneurol.2021.2293","volume":"78","author":"MM Mielke","year":"2021","unstructured":"Mielke MM, Frank RD, Dage JL et al (2021) Comparison of plasma phosphorylated tau species with amyloid and tau positron emission tomography, neurodegeneration, vascular pathology, and cognitive outcomes. JAMA Neurol 78(9):1108\u20131117. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2293","journal-title":"JAMA Neurol"},{"issue":"4","key":"2471_CR48","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1001\/jamaneurol.2020.4986","volume":"78","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, Grothe MJ, Ashton NJ et al (2021a) Longitudinal associations of blood phosphorylated Tau181 and neurofilament light chain with neurodegeneration in Alzheimer disease. JAMA Neurol 78(4):396\u2013406. https:\/\/doi.org\/10.1001\/jamaneurol.2020.4986","journal-title":"JAMA Neurol"},{"issue":"1","key":"2471_CR49","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1093\/brain\/awaa399","volume":"144","author":"A Moscoso","year":"2021","unstructured":"Moscoso A, Grothe MJ, Ashton NJ et al (2021b) Time course of phosphorylated-tau181 in blood across the Alzheimer\u2019s disease spectrum. Brain 144(1):325\u2013339. https:\/\/doi.org\/10.1093\/brain\/awaa399","journal-title":"Brain"},{"key":"2471_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-0838-x","author":"A O'Connor","year":"2020","unstructured":"O\u2019Connor A, Karikari TK, Poole T et al (2020) Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer\u2019s disease: a longitudinal cohort study. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-020-0838-x","journal-title":"Mol Psychiatry"},{"issue":"7","key":"2471_CR51","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/S1474-4422(16)00070-3","volume":"15","author":"B Olsson","year":"2016","unstructured":"Olsson B, Lautner R, Andreasson U et al (2016) CSF and blood biomarkers for the diagnosis of Alzheimer\u2019s disease: a systematic review and meta-analysis. Lancet Neurol 15(7):673\u2013684. https:\/\/doi.org\/10.1016\/S1474-4422(16)00070-3","journal-title":"Lancet Neurol"},{"issue":"8","key":"2471_CR52","doi-asserted-by":"publisher","first-page":"e14398","DOI":"10.15252\/emmm.202114398","volume":"13","author":"R Ossenkoppele","year":"2021","unstructured":"Ossenkoppele R, Reimand J, Smith R et al (2021) Tau PET correlates with different Alzheimer\u2019s disease-related features compared to CSF and plasma p-tau biomarkers. EMBO Mol Med 13(8):e14398. https:\/\/doi.org\/10.15252\/emmm.202114398","journal-title":"EMBO Mol Med"},{"issue":"2","key":"2471_CR53","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1212\/wnl.58.2.192","volume":"58","author":"M Otto","year":"2002","unstructured":"Otto M, Wiltfang J, Cepek L et al (2002) Tau protein and 14-3-3 protein in the differential diagnosis of Creutzfeldt-Jakob disease. Neurology 58(2):192\u2013197. https:\/\/doi.org\/10.1212\/wnl.58.2.192","journal-title":"Neurology"},{"issue":"12","key":"2471_CR54","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Insel PS, Stomrud E et al (2019a) Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol Med 11(12):e11170. https:\/\/doi.org\/10.15252\/emmm.201911170","journal-title":"EMBO Mol Med"},{"issue":"9","key":"2471_CR55","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1001\/jamaneurol.2019.1632","volume":"76","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist S, Janelidze S, Stomrud E et al (2019b) Performance of fully automated plasma assays as screening tests for Alzheimer disease-related beta-amyloid status. JAMA Neurol 76(9):1060\u20131069. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1632","journal-title":"JAMA Neurol"},{"issue":"8","key":"2471_CR56","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1001\/jama.2020.12134","volume":"324","author":"S Palmqvist","year":"2020","unstructured":"Palmqvist S, Janelidze S, Quiroz YT et al (2020) Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA 324(8):772\u2013781. https:\/\/doi.org\/10.1001\/jama.2020.12134","journal-title":"JAMA"},{"issue":"6","key":"2471_CR57","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/s41591-021-01348-z","volume":"27","author":"S Palmqvist","year":"2021","unstructured":"Palmqvist S, Tideman P, Cullen N et al (2021) Prediction of future Alzheimer\u2019s disease dementia using plasma phospho-tau combined with other accessible measures. Nat Med 27(6):1034\u20131042. https:\/\/doi.org\/10.1038\/s41591-021-01348-z","journal-title":"Nat Med"},{"issue":"3","key":"2471_CR58","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/brain\/awy347","volume":"142","author":"JC Park","year":"2019","unstructured":"Park JC, Han SH, Yi D et al (2019) Plasma tau\/amyloid-beta1-42 ratio predicts brain tau deposition and neurodegeneration in Alzheimer\u2019s disease. Brain 142(3):771\u2013786. https:\/\/doi.org\/10.1093\/brain\/awy347","journal-title":"Brain"},{"issue":"5","key":"2471_CR59","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1001\/jamaneurol.2018.4666","volume":"76","author":"MP Pase","year":"2019","unstructured":"Pase MP, Beiser AS, Himali JJ et al (2019) Assessment of plasma total tau level as a predictive biomarker for dementia and related endophenotypes. JAMA Neurol 76(5):598\u2013606. https:\/\/doi.org\/10.1001\/jamaneurol.2018.4666","journal-title":"JAMA Neurol"},{"issue":"9","key":"2471_CR60","doi-asserted-by":"publisher","first-page":"2826","DOI":"10.1093\/brain\/awab163","volume":"144","author":"JB Pereira","year":"2021","unstructured":"Pereira JB, Janelidze S, Stomrud E et al (2021) Plasma markers predict changes in amyloid, tau, atrophy and cognition in non-demented subjects. Brain 144(9):2826\u20132836. https:\/\/doi.org\/10.1093\/brain\/awab163","journal-title":"Brain"},{"issue":"12","key":"2471_CR61","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1136\/jnnp-2020-325537","volume":"92","author":"BS Rauchmann","year":"2021","unstructured":"Rauchmann BS, Schneider-Axmann T, Perneczky R (2021) Alzheimer\u2019s Disease Neuroimaging I. Associations of longitudinal plasma p-tau181 and NfL with tau-PET, Abeta-PET and cognition. J Neurol Neurosurg Psychiatry 92(12):1289\u20131295. https:\/\/doi.org\/10.1136\/jnnp-2020-325537","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10284","key":"2471_CR62","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1016\/S0140-6736(20)32205-4","volume":"397","author":"P Scheltens","year":"2021","unstructured":"Scheltens P, De Strooper B, Kivipelto M et al (2021) Alzheimer\u2019s disease. Lancet 397(10284):1577\u20131590. https:\/\/doi.org\/10.1016\/S0140-6736(20)32205-4","journal-title":"Lancet"},{"issue":"11","key":"2471_CR63","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1016\/j.jalz.2018.07.220","volume":"14","author":"LM Shaw","year":"2018","unstructured":"Shaw LM, Arias J, Blennow K et al (2018) Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer\u2019s disease. Alzheimers Dement 14(11):1505\u20131521. https:\/\/doi.org\/10.1016\/j.jalz.2018.07.220","journal-title":"Alzheimers Dement"},{"issue":"7","key":"2471_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0159099","volume":"11","author":"S Shekhar","year":"2016","unstructured":"Shekhar S, Kumar R, Rai N et al (2016) Estimation of tau and phosphorylated Tau181 in serum of Alzheimer\u2019s disease and mild cognitive impairment patients. PLoS ONE 11(7):e0159099. https:\/\/doi.org\/10.1371\/journal.pone.0159099","journal-title":"PLoS ONE"},{"issue":"8","key":"2471_CR65","doi-asserted-by":"publisher","first-page":"3479","DOI":"10.1021\/acschemneuro.9b00095","volume":"10","author":"Y Shi","year":"2019","unstructured":"Shi Y, Lu X, Zhang L et al (2019) Potential value of plasma amyloid-beta, total tau, and neurofilament light for identification of early Alzheimer\u2019s disease. ACS Chem Neurosci 10(8):3479\u20133485. https:\/\/doi.org\/10.1021\/acschemneuro.9b00095","journal-title":"ACS Chem Neurosci"},{"issue":"Pt 9","key":"2471_CR66","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1093\/brain\/awv181","volume":"138","author":"T Skillb\u00e4ck","year":"2015","unstructured":"Skillb\u00e4ck T, Farahmand BY, Rosen C et al (2015) Cerebrospinal fluid tau and amyloid-beta1-42 in patients with dementia. Brain 138(Pt 9):2716\u20132731. https:\/\/doi.org\/10.1093\/brain\/awv181","journal-title":"Brain"},{"issue":"1","key":"2471_CR67","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s13024-017-0206-8","volume":"12","author":"H Tatebe","year":"2017","unstructured":"Tatebe H, Kasai T, Ohmichi T et al (2017) Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer\u2019s disease and down syndrome. Mol Neurodegen 12(1):63. https:\/\/doi.org\/10.1186\/s13024-017-0206-8","journal-title":"Mol Neurodegen"},{"issue":"1","key":"2471_CR68","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen CE, Verberk IMW, Thijssen EH et al (2022) Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol 21(1):66\u201377. https:\/\/doi.org\/10.1016\/S1474-4422(21)00361-6","journal-title":"Lancet Neurol"},{"issue":"3","key":"2471_CR69","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41591-020-0762-2","volume":"26","author":"EH Thijssen","year":"2020","unstructured":"Thijssen EH, La Joie R, Wolf A et al (2020) Diagnostic value of plasma phosphorylated tau181 in Alzheimer\u2019s disease and frontotemporal lobar degeneration. Nat Med 26(3):387\u2013397. https:\/\/doi.org\/10.1038\/s41591-020-0762-2","journal-title":"Nat Med"},{"issue":"9","key":"2471_CR70","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","volume":"20","author":"EH Thijssen","year":"2021","unstructured":"Thijssen EH, La Joie R, Strom A et al (2021) Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer\u2019s disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study. Lancet Neurol 20(9):739\u2013752. https:\/\/doi.org\/10.1016\/S1474-4422(21)00214-3","journal-title":"Lancet Neurol"},{"issue":"1","key":"2471_CR71","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/s0304-3940(00)01036-3","volume":"285","author":"E Vanmechelen","year":"2000","unstructured":"Vanmechelen E, Vanderstichele H, Davidsson P et al (2000) Quantification of tau phosphorylated at threonine 181 in human cerebrospinal fluid: a sandwich ELISA with a synthetic phosphopeptide for standardization. Neurosci Lett 285(1):49\u201352. https:\/\/doi.org\/10.1016\/s0304-3940(00)01036-3","journal-title":"Neurosci Lett"},{"key":"2471_CR72","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12510","author":"IMW Verberk","year":"2021","unstructured":"Verberk IMW, Misdorp EO, Koelewijn J et al (2021) Characterization of pre-analytical sample handling effects on a panel of Alzheimer\u2019s disease-related blood-based biomarkers: results from the Standardization of Alzheimer\u2019s Blood Biomarkers (SABB) working group. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.12510","journal-title":"Alzheimers Dement"},{"issue":"19","key":"2471_CR73","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1212\/WNL.0b013e3181dd4dd8","volume":"74","author":"AK Wallin","year":"2010","unstructured":"Wallin AK, Blennow K, Zetterberg H, Londos E, Minthon L, Hansson O (2010) CSF biomarkers predict a more malignant outcome in Alzheimer disease. Neurology 74(19):1531\u20131537. https:\/\/doi.org\/10.1212\/WNL.0b013e3181dd4dd8","journal-title":"Neurology"},{"issue":"4","key":"2471_CR74","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1017\/s0317167100013949","volume":"39","author":"L Wu","year":"2012","unstructured":"Wu L, Rosa-Neto P, Hsiung GY et al (2012) Early-onset familial Alzheimer\u2019s disease (EOFAD). Can J Neurol Sci 39(4):436\u2013445. https:\/\/doi.org\/10.1017\/s0317167100013949","journal-title":"Can J Neurol Sci"},{"issue":"1","key":"2471_CR75","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13195-021-00864-x","volume":"13","author":"Z Xiao","year":"2021","unstructured":"Xiao Z, Wu X, Wu W et al (2021) Plasma biomarker profiles and the correlation with cognitive function across the clinical spectrum of Alzheimer\u2019s disease. Alzheimers Res Ther 13(1):123. https:\/\/doi.org\/10.1186\/s13195-021-00864-x","journal-title":"Alzheimers Res Ther"},{"issue":"4","key":"2471_CR76","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.3233\/JAD-170810","volume":"61","author":"CC Yang","year":"2018","unstructured":"Yang CC, Chiu MJ, Chen TF, Chang HL, Liu BH, Yang SY (2018) Assay of plasma phosphorylated tau protein (threonine 181) and total tau protein in early-stage Alzheimer\u2019s disease. J Alzheimers Dis 61(4):1323\u20131332. https:\/\/doi.org\/10.3233\/JAD-170810","journal-title":"J Alzheimers Dis"},{"issue":"1","key":"2471_CR77","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s13195-021-00815-6","volume":"13","author":"I Zerr","year":"2021","unstructured":"Zerr I, Villar-Pique A, Hermann P et al (2021) Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease. Alzheimers Res Ther 13(1):86. https:\/\/doi.org\/10.1186\/s13195-021-00815-6","journal-title":"Alzheimers Res Ther"},{"issue":"1","key":"2471_CR78","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13024-021-00430-x","volume":"16","author":"H Zetterberg","year":"2021","unstructured":"Zetterberg H, Blennow K (2021) Moving fluid biomarkers for Alzheimer\u2019s disease from research tools to routine clinical diagnostics. Mol Neurodegen 16(1):10. https:\/\/doi.org\/10.1186\/s13024-021-00430-x","journal-title":"Mol Neurodegen"},{"issue":"2","key":"2471_CR79","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/alzrt163","volume":"5","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg H, Wilson D, Andreasson U et al (2013) Plasma tau levels in Alzheimer\u2019s disease. Alzheimers Res Ther 5(2):9. https:\/\/doi.org\/10.1186\/alzrt163","journal-title":"Alzheimers Res Ther"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-022-02471-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-022-02471-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-022-02471-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,23]],"date-time":"2022-02-23T16:12:04Z","timestamp":1645632724000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00702-022-02471-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":79,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["2471"],"URL":"https:\/\/doi.org\/10.1007\/s00702-022-02471-y","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"1 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}